

# Elliot Stieglitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/972624/publications.pdf>

Version: 2024-02-01

59  
papers

1,356  
citations

393982

19  
h-index

360668

35  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2389  
citing authors

#	ARTICLE	IF	CITATIONS
1	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	9.4	233
2	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017, 130, 397-407.	0.6	112
3	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	5.8	103
4	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	9.4	97
5	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2127.	5.8	75
6	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 516-524.	0.6	69
7	Genetic predispositions to childhood leukemia. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 270-290.	1.1	68
8	International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant. <i>Analytical Chemistry</i> , 2017, 89, 1724-1733.	3.2	54
9	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 629-636.	0.8	43
10	Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. <i>American Journal of Human Genetics</i> , 2019, 104, 1223-1232.	2.6	43
11	Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i> -Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i> -Rearranged B-ALL. <i>Cancer Discovery</i> , 2021, 11, 2032-2049.	7.7	37
12	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 158-168.	3.2	35
13	Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform. <i>Scientific Reports</i> , 2019, 9, 19606.	1.6	31
14	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory <i>B</i> -cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28718.	0.8	30
15	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	0.6	30
16	Fusion driven JMML: a novel <i>CCDC88C</i> - <i>FLT3</i> fusion responsive to sorafenib identified by RNA sequencing. <i>Leukemia</i> , 2020, 34, 662-666.	3.3	27
17	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27034.	0.8	26
18	Molecular and phenotypic diversity of <i>CBL</i> -mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2022, 107, 178-186.	1.7	25

#	ARTICLE	IF	CITATIONS
19	The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28079.	0.8	22
20	Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 723-730.	1.5	17
21	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
22	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27948.	0.8	13
23	Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. <i>Blood Advances</i> , 2021, 5, 4783-4793.	2.5	13
24	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. <i>Blood</i> , 2014, 123, 1426-1427.	0.6	12
25	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. <i>Leukemia</i> , 2019, 33, 671-685.	3.3	12
26	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	1.3	11
27	ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 290-294.	0.3	9
28	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. <i>Leukemia</i> , 2021, , .	3.3	9
29	In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies. <i>Blood</i> , 2019, 134, 1337-1337.	0.6	8
30	Pulmonary Coccidiomycosis Masquerading as Refractory Metastatic Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e57-e60.	0.3	6
31	Germline <i>RRAS2</i> mutations are not associated with Noonan syndrome. <i>Journal of Medical Genetics</i> , 2016, 53, 728-728.	1.5	6
32	Pediatric MDS: GATA screen the germline. <i>Blood</i> , 2016, 127, 1377-1378.	0.6	5
33	Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature. <i>JCO Precision Oncology</i> , 2020, 4, 1321-1332.	1.5	5
34	Targeting the Ras pathway in pediatric hematologic malignancies. <i>Current Opinion in Pediatrics</i> , 2021, 33, 49-58.	1.0	5
35	NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e808-e811.	0.3	5
36	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018, 132, 1405-1405.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Successful treatment and integrated genomic analysis of an infant with <i>FIP1L1-RARA</i> fusion-associated myeloid neoplasm. <i>Blood Advances</i> , 2022, 6, 1137-1142.	2.5	4
38	Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021, 5, 5507-5518.	2.5	4
39	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. <i>Blood</i> , 2021, 138, 3679-3679.	0.6	4
40	JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1 $\beta$ . <i>Blood Advances</i> , 2021, , .	2.5	3
41	Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2231-2231.	0.6	3
42	DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia: An International Collaborative Analysis and Development of a Common Diagnostic Platform. <i>Blood</i> , 2018, 132, 3093-3093.	0.6	2
43	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2016, 128, 109-109.	0.6	2
44	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. <i>Blood</i> , 2016, 128, 39-39.	0.6	2
45	Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse. <i>Blood</i> , 2021, 138, 1471-1471.	0.6	2
46	Inhibition of BTK and PI3K $\gamma$ impairs the development of human JMML stem and progenitor cells. <i>Molecular Therapy</i> , 2022, 30, 2505-2521.	3.7	2
47	Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021, 5, 3587-3591.	2.5	1
48	Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29499.	0.8	1
49	Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature. <i>Journal of the American Society of Cytopathology</i> , 2022, 11, 281-294.	0.2	1
50	Dysregulation of the transcription factor runx1 in juvenile myelomonocytic leukemia. <i>Experimental Hematology</i> , 2017, 53, S51.	0.2	0
51	Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2013, 122, 1526-1526.	0.6	0
52	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2014, 124, 410-410.	0.6	0
53	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 2699-2699.	0.6	0
54	A Risk Stratified Treatment Algorithm for Patients with Juvenile Myelomonocytic Leukemia. , 2017, 14, .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 26: RUNX1 as a transcriptional target of activated Shp2 (PTPN11) in juvenile myelomonocytic leukemia. , 2017, , .		0
56	Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia. Blood, 2018, 132, 388-388.	0.6	0
57	DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. Blood, 2019, 134, 1693-1693.	0.6	0
58	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. Blood, 2020, 136, 35-36.	0.6	0
59	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. Blood, 2020, 136, 19-20.	0.6	0